Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Cyclophosphamide
Drug: Etoposide
Drug: Melphalan
Drug: Carmustine
Drug: Filgrastim

First Posted Date: 2006-07-10

Last Posted Date: 2017-12-12

Lead Sponsor: Stanford University

Target Recruit Count: 102

Registration Number: NCT00349778

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: cyclophosphamide
Drug: carmustine
Procedure: peripheral blood stem cell transplantation
Radiation: irradiation therapy
Drug: etoposide
Biological: G-CSF
Drug: Cytarabine

First Posted Date: 2006-06-29

Last Posted Date: 2020-07-14

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 473

Registration Number: NCT00345865

Locations: 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States

Cyclophosphamide and Rituximab Followed By Vaccine Therapy in Treating Patients With Chronic Lymphocytic Leukemia

Phase 2

Withdrawn

Conditions: Leukemia

First Posted Date: 2006-06-23

Last Posted Date: 2012-05-03

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Registration Number: NCT00343447

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia

Not Applicable

Conditions: Leukemia

First Posted Date: 2006-06-23

Last Posted Date: 2013-08-26

Lead Sponsor: Universitätsklinikum Hamburg-Eppendorf

Target Recruit Count: 550

Registration Number: NCT00343369

Locations: 🇩🇪
Dr. von Haunersches Kinderspital der Universitaet Muenchen, Munich, Germany
🇩🇪
Kreskrankenhaus Kinderabteilung, Heide, Germany
🇩🇪
Universitaets - Kinderklinik, Leipzig, Germany

and more 13 locations

Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer

Not Applicable

Completed

Conditions: Male Breast Cancer
Nausea and Vomiting
Stage IIIA Breast Cancer
Stage I Breast Cancer
Stage II Breast Cancer

Interventions: Drug: palonosetron hydrochloride
Drug: cyclophosphamide
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Procedure: quality-of-life assessment
Procedure: nausea and vomiting therapy
Procedure: management of therapy complications
Drug: ondansetron hydrochloride
Other: survey administration

First Posted Date: 2006-06-23

Last Posted Date: 2017-07-11

Lead Sponsor: University of Washington

Target Recruit Count: 41

Registration Number: NCT00343863

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant

Phase 2

Completed

Conditions: Aplastic Anemia

Interventions: Drug: cyclophosphamide
Biological: anti-thymocyte globulin
Drug: cyclosporine
Procedure: allogeneic bone marrow transplantation
Drug: methotrexate
Genetic: DNA analysis
Other: flow cytometry
Genetic: polymorphism analysis
Other: laboratory biomarker analysis

First Posted Date: 2006-06-23

Last Posted Date: 2017-04-13

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 21

Registration Number: NCT00343785

Locations: 🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Froedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States

A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies

Phase 1

Completed

Conditions: Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Childhood Burkitt Lymphoma
Accelerated Phase Chronic Myelogenous Leukemia
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Anaplastic Large Cell Lymphoma
Childhood Chronic Myelogenous Leukemia
Chronic Phase Chronic Myelogenous Leukemia

Interventions: Drug: cyclophosphamide
Drug: fludarabine phosphate
Drug: cyclosporine
Drug: mycophenolate mofetil
Other: ex-vivo umbilical cord blood expansion
Procedure: double-unit umbilical cord blood transplantation
Procedure: biopsy
Other: immunologic technique
Other: diagnostic laboratory biomarker analysis

First Posted Date: 2006-06-23

Last Posted Date: 2015-02-11

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 23

Registration Number: NCT00343798

Locations: 🇺🇸
University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, Colorado, United States
🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

and more 1 locations

Lymphodepletion Plus Adoptive Cell Transfer with or Without Dendritic Cell Immunization in Patients with Metastatic Melanoma

Phase 2

Active, not recruiting

Conditions: Melanoma

Interventions: Biological: Dendritic Cell Immunization
Biological: Intrathecal T-Cells
Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Intrathecal Interleukin-2
Biological: T-Cells
Biological: Interleukin-2
Drug: Mesna

First Posted Date: 2006-06-20

Last Posted Date: 2024-10-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1230

Registration Number: NCT00338377

Locations: 🇺🇸
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Combination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2006-06-15

Last Posted Date: 2013-08-02

Lead Sponsor: Cancer Research UK

Target Recruit Count: 56

Registration Number: NCT00337246

Locations: 🇬🇧
Leicester Royal Infirmary, Leicester, England, United Kingdom
🇬🇧
Monklands General Hospital, Airdrie, Scotland, United Kingdom
🇬🇧
Birmingham Heartlands Hospital, Birmingham, England, United Kingdom

and more 13 locations

Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: 5-Fluorouracil
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Paclitaxel
Drug: Epirubicin

First Posted Date: 2006-06-14

Last Posted Date: 2012-02-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 273

Registration Number: NCT00336791

Locations: 🇪🇸
Grupo Español de Investigacion en Cancer de Mama, Madrid, Spain
🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
🇲🇽
Centro Medico Nacional de Occidente, Guadalajara, Mexico

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy